Physician profile
Philip E Kerr
NPI 1073519229
$1,372.10
in general payments reported to CMS, 2019-2025
16 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $103 · 2021: $208 · 2022: $419 · 2023: $50.18 · 2024: $165 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $317.19 | 2019-2024 | Tremfya |
| Genzyme Corporation | $223.10 | 2020-2024 | |
| Abbvie INC. | $175.27 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $101.37 | 2021-2023 | Dupixent |
| Allergan, INC. | $97.33 | 2019 | |
| Leo Pharma INC. | $85.08 | 2021-2025 | Adbry |
| Janssen Scientific Affairs, LLC | $66.89 | 2019-2022 | |
| Galderma Laboratories, L.P. | $54.49 | 2022-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $53.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $53.39 | 2024-2025 | |
| Ucb, INC. | $33.91 | 2025 | Bimzelx |
| Lilly USA, LLC | $32.57 | 2019-2021 | |
| Pfizer INC. | $28.84 | 2024 | |
| Organogenesis INC. | $17.58 | 2021 | |
| Genentech USA, INC. | $17.06 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Kerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.